Literature DB >> 26714913

[Expressions of ZEB2 and C-myc in epithelial ovarian cancer and their clinical significance].

Qinghai Wang1, Huiping Jiang, XiaoJie Deng, Weiyi Fang, Suiqun Guo.   

Abstract

OBJECTIVE: To investigate the expression patterns of ZEB2 and C-myc in epithelial ovarian cancer (EOC) and the associations between their expressions and the pathological features of EOC.
METHODS: The expressions of ZEB2 and C-myc proteins were detected immunohistochemically in 191 cervical cancer tissues and 13 normal ovarian tissues. The relationship between ZEB2 and C-myc protein expressions and the clinicopathological features of EOC was evaluated.
RESULTS: ZEB2 positive expression ratea in EOC tissues and normal ovarian tissues were 49.2% (94/191) and 30.8% (4/13), respectively (P=0.007), and C-myc positive expression rates in the two tissues were 53.9% (103/191) and 15.4% (2/13), respectively (P=0.001). A high expression of ZEB2 was positively correlated with the pathological type of the tumor (P=0.003), FIGO stage (P=0.028), T stage (P=0.002), and N stage (P=0.04), and a high expression of C-myc was positively correlated with FIGO stage (P=0.035), histological grade (P=0.039), and T stage (P=0.002). C-myc and ZEB2 expressions were positively correlated in EOC (P<0.001), and their co-expression in EOC was significantly correlated with T stage (R=0.358, P<0.001) and FIGO stage (P=0.008).
CONCLUSION: ZEB2 and C-myc can promote the progression, invasion and metastasis of EOC, and their combined detection may assist in early diagnosis of EOC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26714913

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  5 in total

1.  MicroRNA-187 exerts tumor-suppressing functions in osteosarcoma by targeting ZEB2.

Authors:  Dan Fei; Kunchi Zhao; Hongping Yuan; Jie Xing; Dongxu Zhao
Journal:  Am J Cancer Res       Date:  2016-12-01       Impact factor: 6.166

2.  MicroRNA-598 inhibits the proliferation and invasion of non-small cell lung cancer cells by directly targeting ZEB2.

Authors:  Xiangdong Tong; Peng Su; Haitao Yang; Fusheng Chi; Lin Shen; Xiao Feng; Hongqian Jiang; Xiuchun Zhang; Zhenyuan Wang
Journal:  Exp Ther Med       Date:  2018-10-03       Impact factor: 2.751

3.  FSH receptor binding inhibitor impacts K-Ras and c-Myc of ovarian cancer and signal pathway.

Authors:  Suocheng Wei; Xiaoyun Shen; Luju Lai; Haoqin Liang; Yingying Deng; Zhuandi Gong; Tuanjie Che
Journal:  Oncotarget       Date:  2018-04-27

4.  Reactivation of microRNA-506 inhibits gastric carcinoma cell metastasis through ZEB2.

Authors:  Gui-Jun Wang; Bao-Ping Jiao; Yang-Jun Liu; Yan-Rong Li; Bei-Bei Deng
Journal:  Aging (Albany NY)       Date:  2019-03-28       Impact factor: 5.682

5.  Effects of naringin on reversing cisplatin resistance and the Wnt/β-catenin pathway in human ovarian cancer SKOV3/CDDP cells.

Authors:  Hong Zhu; Xia Zou; ShiXin Lin; Xin Hu; Jun Gao
Journal:  J Int Med Res       Date:  2020-10       Impact factor: 1.671

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.